Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphoid 1

Interventions

Imatinib Mesylate 86nilotinib 59fludarabine phosphate 46Cyclophosphamide 45Mycophenolic Acid 37Whole-Body Irradiation 35Dasatinib 32fludarabine 31Tacrolimus 29Cyclosporine 24Busulfan 23Peripheral Blood Stem Cell Transplantation 22Methotrexate 20bosutinib 18Cytarabine 18Granulocyte Colony-Stimulating Factor 16Filgrastim 16Melphalan 14thymoglobulin 13Antilymphocyte Serum 13Stem Cell Transplantation 12sargramostim 11Thiotepa 11Interferon-alpha 10Cord Blood Stem Cell Transplantation 9asciminib 8Cyclosporins 8ponatinib 7Sirolimus 7Radiotherapy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × tozasertib × Clear all
NCT00111683 2015-08-25

MK0457 in Patients With Leukemia (0457-003)

Merck Sharp & Dohme LLC

Phase 1 Completed
28 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Lymphoid, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡